Canada Pension Plan Investment Board raised its holdings in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 25.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 207,564 shares of the medical instruments supplier’s stock after purchasing an additional 41,454 shares during the quarter. Canada Pension Plan Investment Board owned about 0.29% of West Pharmaceutical Services worth $68,370,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also made changes to their positions in the company. Fidelis Capital Partners LLC acquired a new stake in shares of West Pharmaceutical Services during the first quarter worth $27,000. Crewe Advisors LLC lifted its stake in shares of West Pharmaceutical Services by 322.7% in the 2nd quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 71 shares during the period. Quarry LP boosted its holdings in shares of West Pharmaceutical Services by 155.3% in the fourth quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock valued at $34,000 after acquiring an additional 59 shares in the last quarter. Hazlett Burt & Watson Inc. purchased a new position in West Pharmaceutical Services during the first quarter worth about $40,000. Finally, Northwest Investment Counselors LLC acquired a new stake in West Pharmaceutical Services in the first quarter valued at about $40,000. 93.90% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at West Pharmaceutical Services
In other West Pharmaceutical Services news, VP Charles Witherspoon sold 1,029 shares of the stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $300.00, for a total value of $308,700.00. Following the completion of the transaction, the vice president now directly owns 1,478 shares of the company’s stock, valued at $443,400. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.53% of the company’s stock.
West Pharmaceutical Services Stock Performance
West Pharmaceutical Services (NYSE:WST – Get Free Report) last released its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.22). The business had revenue of $702.10 million during the quarter, compared to analysts’ expectations of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The company’s revenue was down 6.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.11 EPS. Research analysts expect that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current year.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
Further Reading
- Five stocks we like better than West Pharmaceutical Services
- Overbought Stocks Explained: Should You Trade Them?
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- MarketBeat Week in Review – 9/16 – 9/20
- 3 Small Caps With Big Return Potential
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.